NS004 | CAS#141797-92-4

MedKoo Cat#: 532362 | Name: NS004

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NS004 is a large-conductance K+ channel opener which is an inhibitor of mitochondrial function in glioma cells.

Chemical Structure

NS004

CAS#141797-92-4

Theoretical Analysis

MedKoo Cat#: 532362

Name: NS004

CAS#: 141797-92-4

Chemical Formula: C14H8ClF3N2O2

Exact Mass: 328.0226

Molecular Weight: 328.68

Elemental Analysis: C, 51.16; H, 2.45; Cl, 10.79; F, 17.34; N, 8.52; O, 9.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

NS004; NS 004; NS-004.

IUPAC/Chemical Name

1-(5-chloro-2-hydroxyphenyl)-5-(trifluoromethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one

InChi Key

WYLYBVMNGZOYOH-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H8ClF3N2O2/c15-8-2-4-12(21)11(6-8)20-10-3-1-7(14(16,17)18)5-9(10)19-13(20)22/h1-6,21H,(H,19,22)

SMILES Code

O=C1N(C2=CC(Cl)=CC=C2O)C3=CC=C(C(F)(F)F)C=C3N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 328.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Nardi A, Calderone V, Chericoni S, Morelli I. Natural modulators of large-conductance calcium-activated potassium channels. Planta Med. 2003 Oct;69(10):885-92. Review. PubMed PMID: 14648389. 2: Dérand R, Bulteau-Pignoux L, Becq F. Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. PubMed PMID: 14502435. 3: Debska G, Kicinska A, Dobrucki J, Dworakowska B, Nurowska E, Skalska J, Dolowy K, Szewczyk A. Large-conductance K+ channel openers NS1619 and NS004 as inhibitors of mitochondrial function in glioma cells. Biochem Pharmacol. 2003 Jun 1;65(11):1827-34. PubMed PMID: 12781334. 4: Al-Nakkash L, Hu S, Li M, Hwang TC. A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogs. J Pharmacol Exp Ther. 2001 Feb;296(2):464-72. PubMed PMID: 11160632. 5: Villette H, Lelièvre LG. Biochemical evidence for ATPase activity in CFTR-enriched apical membrane vesicles from tracheal epithelium. Biochim Biophys Acta. 2000 Jul 31;1467(1):7-17. PubMed PMID: 10930504. 6: Devor DC, Bridges RJ, Pilewski JM. Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. Am J Physiol Cell Physiol. 2000 Aug;279(2):C461-79. PubMed PMID: 10913013. 7: Lawson K. Potassium channel openers as potential therapeutic weapons in ion channel disease. Kidney Int. 2000 Mar;57(3):838-45. Review. PubMed PMID: 10720937. 8: Warth R, Hamm K, Bleich M, Kunzelmann K, von Hahn T, Schreiber R, Ullrich E, Mengel M, Trautmann N, Kindle P, Schwab A, Greger R. Molecular and functional characterization of the small Ca(2+)-regulated K+ channel (rSK4) of colonic crypts. Pflugers Arch. 1999 Sep;438(4):437-44. PubMed PMID: 10519135. 9: Hardy P, Abran D, Hou X, Lahaie I, Peri KG, Asselin P, Varma DR, Chemtob S. A major role for prostacyclin in nitric oxide-induced ocular vasorelaxation in the piglet. Circ Res. 1998 Oct 5;83(7):721-9. PubMed PMID: 9758642. 10: He Z, Raman S, Guo Y, Reenstra WW. Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms. Am J Physiol. 1998 Oct;275(4 Pt 1):C958-66. PubMed PMID: 9755049. 11: Hu S, Kim HS. On the mechanism of the differential effects of NS004 and NS1608 in smooth muscle cells from guinea pig bladder. Eur J Pharmacol. 1996 Dec 30;318(2-3):461-8. PubMed PMID: 9016939. 12: Gribkoff VK, Lum-Ragan JT, Boissard CG, Post-Munson DJ, Meanwell NA, Starrett JE Jr, Kozlowski ES, Romine JL, Trojnacki JT, Mckay MC, Zhong J, Dworetzky SI. Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Mol Pharmacol. 1996 Jul;50(1):206-17. PubMed PMID: 8700114. 13: Müller M, Madan D, Levitan IB. State-dependent modulation of mSlo, a cloned calcium-dependent potassium channel. Neuropharmacology. 1996;35(7):877-86. PubMed PMID: 8938718. 14: Hu S, Kim HS, Fink CA. Differential effects of the BKCa channel openers NS004 and NS1608 in porcine coronary arterial cells. Eur J Pharmacol. 1995 Dec 27;294(1):357-60. PubMed PMID: 8788454. 15: Trivedi S, Potter-Lee L, Li JH, Yasay GD, Russell K, Ohnmacht CJ, Empfield JR, Trainor DA, Kau ST. Calcium dependent K-channels in guinea pig and human urinary bladder. Biochem Biophys Res Commun. 1995 Aug 15;213(2):404-9. PubMed PMID: 7544120. 16: Champigny G, Imler JL, Puchelle E, Dalemans W, Gribkoff V, Hinnrasky J, Dott K, Barbry P, Pavirani A, Lazdunski M. A change in gating mode leading to increased intrinsic Cl- channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease. EMBO J. 1995 Jun 1;14(11):2417-23. PubMed PMID: 7540133; PubMed Central PMCID: PMC398355. 17: Dworetzky SI, Trojnacki JT, Gribkoff VK. Cloning and expression of a human large-conductance calcium-activated potassium channel. Brain Res Mol Brain Res. 1994 Nov;27(1):189-93. PubMed PMID: 7877450. 18: McKay MC, Dworetzky SI, Meanwell NA, Olesen SP, Reinhart PH, Levitan IB, Adelman JP, Gribkoff VK. Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004. J Neurophysiol. 1994 May;71(5):1873-82. PubMed PMID: 8064354. 19: Gribkoff VK, Champigny G, Barbry P, Dworetzky SI, Meanwell NA, Lazdunski M. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J Biol Chem. 1994 Apr 15;269(15):10983-6. PubMed PMID: 7512555.